Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced that it received a Sept. 2 Notice of Publication from the U.S. Patent and Trademark Office (USPTO) for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The trademarks will be published in the USPTO Trademark Official Gazette, and if no objections are filed during the 30-day opposition period, the USPTO is expected to issue a Notice of Allowance.
The fentanyl system incorporates Nutriband's AVERSA abuse-deterrent transdermal technology and is being developed as a patch designed to deter abuse and misuse and reduce the risk of accidental exposure to transdermal fentanyl. Nutriband said the product has potential peak annual U.S. sales of $80 million to $200 million, while its AVERSA technology is protected by patents issued in 46 countries.
This milestone is crucial for Nutriband as it strengthens its intellectual property portfolio and brand identity for a product that addresses a significant public health concern: the abuse and diversion of prescription opioids. The fentanyl patch is intended to provide pain relief while incorporating features that make it difficult to extract the active ingredient for illicit use. By securing trademark protection, Nutriband is positioning itself to establish a recognized brand in the market, which is essential for commercial success.
The potential market for abuse-deterrent opioids is substantial, given regulatory and societal pressures to curb opioid misuse. The U.S. Food and Drug Administration has encouraged the development of abuse-deterrent formulations, and products that meet these standards may receive priority review and market exclusivity. Nutriband's AVERSA technology is designed to be incorporated into any transdermal patch, offering a versatile solution for drugs with abuse potential.
The Notice of Publication is a procedural step in the trademark registration process, but it signals that the USPTO has found no immediate conflicts with existing marks. The 30-day opposition period allows third parties to challenge the trademarks if they believe they will be harmed. If no opposition is filed, the marks will proceed to registration, providing Nutriband with exclusive rights to use the names in commerce.
For investors, this development underscores Nutriband's progress in advancing its lead product candidate toward commercialization. The company has previously highlighted the product's potential to generate significant revenue, and this trademark advancement is a key part of its overall strategy to protect its intellectual property and build a recognizable brand. As the opioid crisis continues to spur demand for safer pain management options, Nutriband's focus on abuse deterrence could differentiate it from competitors.
The company's newsroom provides updates on NTRB developments, and further information about the trademark process can be found on the USPTO website. Nutriband's commitment to addressing opioid abuse through innovative transdermal technology positions it as a notable player in the pharmaceutical industry.
